WO2022135545A1 - 〈无细胞脂肪提取物对勃起功能障碍的治疗用途〉 - Google Patents

〈无细胞脂肪提取物对勃起功能障碍的治疗用途〉 Download PDF

Info

Publication number
WO2022135545A1
WO2022135545A1 PCT/CN2021/140982 CN2021140982W WO2022135545A1 WO 2022135545 A1 WO2022135545 A1 WO 2022135545A1 CN 2021140982 W CN2021140982 W CN 2021140982W WO 2022135545 A1 WO2022135545 A1 WO 2022135545A1
Authority
WO
WIPO (PCT)
Prior art keywords
cell
fat extract
extract
another preferred
free fat
Prior art date
Application number
PCT/CN2021/140982
Other languages
English (en)
French (fr)
Inventor
龚璇
张文杰
Original Assignee
上海萨美细胞技术有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 上海萨美细胞技术有限公司 filed Critical 上海萨美细胞技术有限公司
Publication of WO2022135545A1 publication Critical patent/WO2022135545A1/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/35—Fat tissue; Adipocytes; Stromal cells; Connective tissues
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • the invention relates to the field of medicine, in particular to the therapeutic use of acellular fat extract for erectile dysfunction.
  • ED Male erectile dysfunction
  • the cavernous nerve (CN) of the penis is the main nerve that induces penile erection, and CN injury of various reasons can cause neurogenic erectile dysfunction (NED).
  • NED neurogenic erectile dysfunction
  • pelvic surgery such as radical prostatectomy can easily damage the CN, thereby causing postoperative NED.
  • the prior art lacks effective therapeutic drugs for erectile dysfunction caused by damage to the cavernous nerve of the penis, thus limiting the effective treatment of patients with erectile dysfunction.
  • the purpose of the present invention is to provide the use of a cell-free fat extract in preventing and/or treating erectile dysfunction and penile cavernosal nerve damage.
  • a cell-free adipose extract for the preparation of a composition or formulation for one or more uses selected from the group consisting of: (i) prophylaxis and /or treatment of erectile dysfunction; (ii) prevention and/or treatment of damage to the cavernous nerve of the penis.
  • the erectile dysfunction is male erectile dysfunction.
  • the erectile dysfunction includes erectile dysfunction caused by damage to the cavernosal nerve of the penis.
  • the cell-free fat extract is a cell-free fat extract prepared from human or non-human mammalian fat.
  • the non-human mammal is monkey, orangutan, cow, pig, dog, sheep, mouse or rabbit.
  • compositions or preparations include pharmaceutical compositions or preparations, food compositions or preparations, health product compositions or preparations, or dietary supplements.
  • composition or preparation further includes a pharmaceutically, food, health product or dietary acceptable carrier.
  • the dosage form of the composition or preparation is an oral preparation, an external preparation or an injection preparation.
  • the injection preparation is an intravenous injection or an intramuscular injection.
  • the injection preparation is a penile corpus cavernosum injection preparation.
  • the dosage form of the composition or preparation is a solid dosage form, a semi-solid dosage form, or a liquid dosage form, such as solution, gel, cream, lotion, ointment, cream, paste, cake, powder, Patches etc.
  • the dosage form of the composition or preparation is powder, granule, capsule, injection, tincture, oral liquid, tablet or lozenge.
  • composition or preparation is administered externally, topically, or by injection.
  • the injection method is corpus cavernosum injection.
  • the cell-free fat extract does not contain cells and does not contain lipid droplets.
  • the lipid droplets are oil droplets released after fat cells are disrupted.
  • the "does not contain lipid droplets" means that in the cell-free fat extract, the volume of oil droplets accounts for less than 1% of the total liquid, preferably less than 0.5%, more preferably less than 0.1%.
  • the cells are selected from the group consisting of endothelial cells, adipose stem cells, macrophages, and stromal cells.
  • the "cell-free” refers to the average number of cells in 1 ml of cell-free fat extract ⁇ 1, preferably ⁇ 0.5, more preferably ⁇ 0.1, or 0.
  • the cell-free fat extract is a naturally-obtained nano-fat extract without added components.
  • the "no added components” means that, except for the rinsing step, no solution, solvent, small molecule, chemical agent, and biological additive are added during the preparation of the fat extract.
  • the cell-free adipose extract is prepared by centrifuging adipose tissue after emulsification.
  • the cell-free fat extract contains one or more components selected from the group consisting of IGF-1, BDNF, GDNF, TGF- ⁇ 1, HGF, bFGF, VEGF, TGF- ⁇ 1 , PDGF, EGF, NT-3, GH, G-CSF, or a combination thereof.
  • the cell-free fat extract contains, but is not limited to, one or more components selected from the group consisting of IGF-1, BDNF, GDNF, bFGF, VEGF, TGF- ⁇ 1, HGF , PDGF, or a combination thereof.
  • the cell-free fat extract is a cell-free fat extract.
  • the concentration of the IGF-1 is 5000-30000pg/ml, preferably 6000-20000pg/ml, more preferably 7000-15000pg/ml , more preferably 8000-12000pg/ml, more preferably 9000-11000pg/ml, more preferably 9500-10500pg/ml.
  • the concentration of BDNF is 800-5000pg/ml, preferably 1000-4000pg/ml, more preferably 1200-2500pg/ml, more Preferably 1400-2000 pg/ml, more preferably 1600-2000 pg/ml, more preferably 1700-1850 pg/ml.
  • the concentration of GDNF is 800-5000pg/ml, preferably 1000-4000pg/ml, more preferably 1200-2500pg/ml, more Preferably 1400-2000 pg/ml, more preferably 1600-2000 pg/ml, more preferably 1700-1900 pg/ml.
  • the concentration of the bFGF is 50-600pg/ml, preferably 100-500pg/ml, more preferably 120-400pg/ml, more Preferably 150-300 pg/ml, more preferably 200-280 pg/ml, more preferably 220-260 pg/ml.
  • the concentration of the VEGF is 50-500pg/ml, preferably 100-400pg/ml, more preferably 120-300pg/ml, more Preferably 150-250 pg/ml, more preferably 170-230 pg/ml, more preferably 190-210 pg/ml.
  • the concentration of TGF- ⁇ 1 is 200-3000pg/ml, preferably 400-2000pg/ml, more preferably 600-1500pg/ml , more preferably 800-1200pg/ml, more preferably 800-1100pg/ml, more preferably 900-1000pg/ml.
  • the concentration of the HGF is 200-3000pg/ml, preferably 400-2000pg/ml, more preferably 600-1500pg/ml, more Preferably 600-1200 pg/ml, more preferably 800-1000 pg/ml, more preferably 850-950 pg/ml.
  • the concentration of PDGF is 50-600pg/ml, preferably 80-400pg/ml, more preferably 100-300pg/ml, more Preferably 140-220 pg/ml, more preferably 160-200 pg/ml, more preferably 170-190 pg/ml.
  • the weight ratio of IGF-1 to VEGF is 20-100:1, preferably 30-70:1, more preferably 40-60:1, most preferably 45-55: 1.
  • the weight ratio of BDNF to VEGF is 2-20:1, preferably 4-15:1, more preferably 6-12:1, and most preferably 8-9.5:1.
  • the weight ratio of GDNF to VEGF is 2-20:1, preferably 4-15:1, more preferably 6-12:1, and most preferably 8.5-9.5:1.
  • the weight ratio of bFGF to VEGF is 0.2-8:1, preferably 0.5-5:1, more preferably 0.6-2:1, more preferably 0.8-1.6:1, Optimally 1-1.5:1.
  • the weight ratio of TGF- ⁇ 1 to VEGF is 1-20:1, preferably 1-15:1, more preferably 1-10:1, more preferably 2-8: 1, preferably 4-6:1.
  • the weight ratio of HGF to VEGF is 1-20:1, preferably 1-15:1, more preferably 1-10:1, more preferably 2-8:1, More preferably 4-5.5:1.
  • the weight ratio of PDGF to VEGF is 0.1-3:1, preferably 0.2-2:1, more preferably 0.4-1.5:1, and most preferably 0.7-1.2:1.
  • the cell-free fat extract is prepared by the following method:
  • Emulsifying the intermediate layer to obtain an emulsified fat mixture also referred to as nano-fat
  • a second aspect of the present invention provides a method for preparing a cell-free fat extract, the method comprising the steps of:
  • Emulsifying the intermediate layer to obtain an emulsified fat mixture also referred to as nano-fat
  • the cell-free fat extract is as described in the first aspect of the present invention.
  • the centrifugation is performed at 800-2500g, preferably 800-2000g, more preferably 1000-1500g, and most preferably 1100-1300g.
  • the centrifugation time is 1-15 minutes, preferably 1-10 minutes, more preferably 1-8 minutes, and optimally 1-5 minutes.
  • the temperature of the centrifugation is 2-6°C.
  • the emulsification is mechanical emulsification.
  • the mechanical emulsification is performed mechanically by repeated blowing through a syringe (eg 20-200 times, preferably 20-150 times, more preferably 20-100 times, more preferably 30-50 times). emulsification.
  • the blowing method is to repeatedly push and beat at a constant speed with two 10ml injection syringes connected to a tee tube.
  • the emulsification is a method of crushing by a tissue homogenizer.
  • the emulsified fat mixture is further frozen and then thawed.
  • the thawed mixture is used for centrifugation after thawing after freezing.
  • the freezing temperature is -50°C to -120°C, preferably -60°C to -100°C, more preferably -70°C to -90°C.
  • the thawing temperature is 20-40°C, preferably 25-40°C, more preferably 37°C.
  • the number of cycles of thawing after freezing is 1-5 times (preferably 1, 2, 3 or 4 times).
  • the emulsified fat mixture is layered into four layers, the first layer is an oil layer, the second layer is a residual adipose tissue layer, and the third layer is a liquid layer layer (ie, the middle liquid layer), and the fourth layer is the cell/tissue debris sedimentation layer.
  • the centrifugation is performed at 800-2500g, preferably 800-2000g, more preferably 1000-1500g, and most preferably 1100-1300g.
  • the centrifugation time is 1-15 minutes, preferably 1-10 minutes, more preferably 2-8 minutes, and optimally 3-7 minutes.
  • the temperature of the centrifugation is 2-6°C.
  • the first layer, the second layer, the third layer and the fourth layer are arranged in order from top to bottom.
  • the intermediate liquid layer is a transparent or substantially transparent layer.
  • the filter bag in the step (6), can remove the adipocytes in the primary fat extract.
  • the filtration and sterilization are performed through a filter (eg, a 0.22 ⁇ m microporous membrane).
  • a filter eg, a 0.22 ⁇ m microporous membrane
  • the filter is a microporous membrane filter.
  • the pore size of the microporous filter membrane is 0.05-0.8 ⁇ m, preferably 0.1-0.5 ⁇ m, more preferably 0.1-0.4 ⁇ m, more preferably 0.15-0.3 ⁇ m, more preferably 0.2-0.25 ⁇ m, optimally 0.22 ⁇ m.
  • the filtration and sterilization are firstly passed through a first filter that can filter out cells, and then passed through a second filter that can filter out pathogens (such as bacteria).
  • filter eg, 0.22 ⁇ m filter.
  • the step (6) further includes sub-packaging the fat extract to form a sub-packaged product.
  • the subpackaged extract can be stored at -20°C for later use; it can be used directly after thawing at low temperature (such as -4°C) or normal temperature, or it can be stored at low temperature (such as 4°C) for a period of time after thawing, and then used ).
  • the third aspect of the present invention provides a cell-free fat extract, which is prepared by the method described in the second aspect of the present invention.
  • the fourth aspect of the present invention provides a composition or formulation comprising (a) the cell-free fat extract according to the third aspect of the present invention; and (b) pharmaceutically, food, Nutraceutical or dietary acceptable carrier or excipient.
  • the composition is a pharmaceutical composition, a food composition, a health product composition or a dietary supplement.
  • the dosage form of the composition or preparation is an oral preparation, an external preparation or an injection preparation.
  • the dosage form of the composition or preparation is powder, granule, capsule, injection, tincture, oral liquid, tablet or lozenge.
  • the injection is an intravenous injection or an intramuscular injection.
  • the dosage form of the composition or preparation is a solid dosage form, a semi-solid dosage form, or a liquid dosage form, such as solution, gel, cream, lotion, ointment, cream, paste, cake, powder, Patches etc.
  • the mass percentage of the cell-free fat extract is 5 wt %, preferably 1-20 wt %, based on the total weight of the composition or preparation.
  • the fifth aspect of the present invention provides a method for preparing the composition or preparation according to the fourth aspect of the present invention, the method comprising the steps of: mixing the cell-free fat extract according to the third aspect of the present invention with a pharmaceutical It is mixed with acceptable carriers or excipients on food, health product or diet to form a composition or preparation.
  • the sixth aspect of the present invention provides a method for (i) preventing and/or treating erectile dysfunction; and/or (ii) preventing and/or treating damage to the cavernosal nerve of the penis, by administering to a subject in need the method described in the third aspect of the present invention
  • the cell-free adipose extract of the aspect is provided.
  • the subject is a human or a non-human mammal.
  • the non-human mammals include rodents, such as rats and mice.
  • the administration mode is oral administration, topical administration or injection administration.
  • the administration is corpus cavernosum injection administration.
  • Figure 1 shows the results of ICP/MAP pressure measurement of rats in each group.
  • a cell-free fat extract has an excellent therapeutic effect on erectile dysfunction.
  • the study of the examples of the present invention shows that the cell-free fat extract of the present invention has an excellent improvement effect on the injury of the cavernosal nerve, and has an excellent therapeutic effect on the erectile dysfunction caused by the injury of the cavernous nerve of the penis.
  • the present invention has been completed on this basis.
  • the terms “comprising,” “including,” and “containing” are used interchangeably to include not only open definitions, but also semi-closed, and closed definitions. In other words, the terms include “consisting of”, “consisting essentially of”.
  • prevention refers to a method of preventing the onset of a disease and/or its attendant symptoms or protecting a subject from acquiring a disease. "Prevention” as used herein also includes delaying the onset of the disease and/or its attendant symptoms and reducing the risk of the disease in a subject.
  • Treatment includes delaying and stopping the progression of the disease, or eliminating the disease, and does not require 100% inhibition, elimination and reversal.
  • the cell-free adipose extract of the invention reduces, inhibits and/or reverses erectile dysfunction, eg, by at least about 10%, at least About 30%, at least about 50%, or at least about 80%.
  • IGF-1 insulin-like growth factors-1
  • BDNF brain-derived neurotrophic factor
  • GDNF glial cellline-derived neurotrophic factor
  • bFGF basic fibroblast growth factor
  • VEGF vascular endothelial growth factor
  • TGF- ⁇ 1 is referred to as transforming growth factor- ⁇ 1.
  • HGF Hepatocyte Growth Factor
  • PDGF Platelet derived growth factor
  • EGF Epidermal Growth Factor
  • NT-3 As used in the text, the term "NT-3" is referred to as neurotrophins-3.
  • GH Growth Hormone
  • G-CSF granulocyte colony stimulating factor
  • CEFFE Cell free fat extract
  • the terms "cell-free adipose extract of the present invention,” “extract of the present invention,” “fat extract of the present invention,” and the like are used interchangeably to refer to the process during the preparation of the fat extract (other than the rinsing step). )
  • An adipose tissue-derived extract (or extract) prepared without the addition of any solutions, solvents, small molecules, chemicals, and biological additives.
  • a typical method for preparing the extract of the present invention is as described above in the second aspect of the present invention.
  • the extract of the present invention does not have to add any additives (or added components) during the preparation process, some or small amounts of safe substances (such as small amounts) that do not negatively or adversely affect the activity of the extract of the present invention may also be added. water).
  • the cell-free fat extract of the present invention can be derived from human adipose tissue, which is purified from nano-fat by removing oil and cell/extracellular matrix fractions after centrifugation, and is a cell-free, easy-to-prepare, rich in various a growth factor liquid.
  • the cell-free fat extract is a cell-free fat extract.
  • the cell-free adipose extract of the present invention various cytokines may be included.
  • the cell-free adipose extract comprises IGF-1, BDNF, GDNF, TGF- ⁇ , HGF, bFGF, VEGF, TGF- ⁇ 1, PDGF, EGF, NT-3, GH and G-CSF one or more.
  • the concentration of the IGF-1 is 5000-30000pg/ml, preferably 6000-20000pg/ml, more preferably 7000-15000pg/ml , more preferably 8000-12000pg/ml, more preferably 9000-11000pg/ml, more preferably 9500-10500pg/ml.
  • the concentration of BDNF is 800-5000pg/ml, preferably 1000-4000pg/ml, more preferably 1200-2500pg/ml, more Preferably 1400-2000 pg/ml, more preferably 1600-2000 pg/ml, more preferably 1700-1850 pg/ml.
  • the concentration of GDNF is 800-5000pg/ml, preferably 1000-4000pg/ml, more preferably 1200-2500pg/ml, more Preferably 1400-2000 pg/ml, more preferably 1600-2000 pg/ml, more preferably 1700-1900 pg/ml.
  • the concentration of the bFGF is 50-600pg/ml, preferably 100-500pg/ml, more preferably 120-400pg/ml, more Preferably 150-300 pg/ml, more preferably 200-280 pg/ml, more preferably 220-260 pg/ml.
  • the concentration of the VEGF is 50-500pg/ml, preferably 100-400pg/ml, more preferably 120-300pg/ml, more Preferably 150-250 pg/ml, more preferably 170-230 pg/ml, more preferably 190-210 pg/ml.
  • the concentration of TGF- ⁇ 1 is 200-3000pg/ml, preferably 400-2000pg/ml, more preferably 600-1500pg/ml , more preferably 800-1200pg/ml, more preferably 800-1100pg/ml, more preferably 900-1000pg/ml.
  • the concentration of the HGF is 200-3000pg/ml, preferably 400-2000pg/ml, more preferably 600-1500pg/ml, more Preferably 600-1200 pg/ml, more preferably 800-1000 pg/ml, more preferably 850-950 pg/ml.
  • the concentration of PDGF is 50-600pg/ml, preferably 80-400pg/ml, more preferably 100-300pg/ml, more Preferably 140-220 pg/ml, more preferably 160-200 pg/ml, more preferably 170-190 pg/ml.
  • the weight ratio of IGF-1 to VEGF is 20-100:1, preferably 30-70:1, more preferably 40-60:1, most preferably 45-55: 1.
  • the weight ratio of BDNF to VEGF is 2-20:1, preferably 4-15:1, more preferably 6-12:1, and most preferably 8-9.5:1.
  • the weight ratio of GDNF to VEGF is 2-20:1, preferably 4-15:1, more preferably 6-12:1, and most preferably 8.5-9.5:1.
  • the weight ratio of bFGF to VEGF is 0.2-8:1, preferably 0.5-5:1, more preferably 0.6-2:1, more preferably 0.8-1.6:1, Optimally 1-1.5:1.
  • the weight ratio of TGF- ⁇ 1 to VEGF is 1-20:1, preferably 1-15:1, more preferably 1-10:1, more preferably 2-8: 1, preferably 4-6:1.
  • the weight ratio of HGF to VEGF is 1-20:1, preferably 1-15:1, more preferably 1-10:1, more preferably 2-8:1, More preferably 4-5.5:1.
  • the weight ratio of PDGF to VEGF is 0.1-3:1, preferably 0.2-2:1, more preferably 0.4-1.5:1, and most preferably 0.7-1.2:1.
  • the cell-free fat extract of the present invention is prepared by the method as described in the second aspect of the present invention.
  • the cell-free fat extracts of the present invention are prepared by the following methods:
  • Emulsifying the intermediate layer to obtain an emulsified fat mixture also referred to as nano-fat
  • the centrifugation is performed at 800-2500g, preferably 800-2000g, more preferably 1000-1500g, and most preferably 1100-1300g.
  • the centrifugation time is 1-15 minutes, preferably 1-10 minutes, more preferably 1-8 minutes, and optimally 1-5 minutes.
  • the emulsification is mechanical emulsification.
  • the mechanical emulsification is performed mechanically by repeated blowing through a syringe (eg 20-200 times, preferably 20-150 times, more preferably 20-100 times, more preferably 30-50 times). emulsification.
  • the blowing method is to repeatedly push and beat at a constant speed with two 10ml injection syringes connected to a tee tube.
  • the emulsification is a method of crushing by a tissue homogenizer.
  • the emulsified fat mixture is further frozen and then thawed.
  • the thawed mixture is used for centrifugation after thawing after freezing.
  • the freezing temperature is -50°C to -120°C, preferably -60°C to -100°C, more preferably -70°C to -90°C.
  • the thawing temperature is 20-40°C, preferably 25-40°C, more preferably 37°C.
  • the number of cycles of thawing after freezing is 1-5 times (preferably 1, 2, 3 or 4 times).
  • the emulsified fat mixture is layered into four layers, the first layer is an oil layer, the second layer is a residual adipose tissue layer, and the third layer is a liquid layer layer (ie, the middle liquid layer), and the fourth layer is the cell/tissue debris sedimentation layer.
  • the centrifugation is performed at 800-2500g, preferably 800-2000g, more preferably 1000-1500g, and most preferably 1100-1300g.
  • the centrifugation time is 1-15 minutes, preferably 1-10 minutes, more preferably 2-8 minutes, and optimally 3-7 minutes.
  • the first layer, the second layer, the third layer and the fourth layer are arranged in order from top to bottom.
  • the intermediate liquid layer is a transparent or substantially transparent layer.
  • the filter bag in the step (6), can remove the adipocytes in the primary fat extract.
  • the filtration and sterilization are performed through a filter (eg, a 0.22 ⁇ m microporous membrane).
  • a filter eg, a 0.22 ⁇ m microporous membrane
  • the filter is a microporous membrane filter.
  • the pore size of the microporous filter membrane is 0.05-0.8 ⁇ m, preferably 0.1-0.5 ⁇ m, more preferably 0.1-0.4 ⁇ m, more preferably 0.15-0.3 ⁇ m, more preferably 0.2-0.25 ⁇ m, optimally 0.22 ⁇ m.
  • the filtration and sterilization are firstly passed through a first filter that can filter out cells, and then passed through a second filter that can filter out pathogens (such as bacteria).
  • filter eg, 0.22 ⁇ m filter.
  • the step (6) further includes sub-packaging the fat extract to form a sub-packaged product.
  • the subpackaged extract can be stored at -20°C for later use; it can be used directly after thawing at low temperature (such as -4°C) or normal temperature, or it can be stored at low temperature (such as 4°C) for a period of time after thawing, and then used ).
  • the present invention provides the use of a cell-free adipose extract for the preparation of a composition or formulation for one or more uses selected from the group consisting of: (i) preventing and/or treating erections dysfunction; (ii) preventing and/or treating damage to the cavernous nerve of the penis.
  • the erectile dysfunction is human male erectile dysfunction.
  • the erectile dysfunction includes erectile dysfunction caused by damage to the cavernous nerve of the penis.
  • the cell-free fat extract of the present invention can prevent and/or treat erectile dysfunction by preventing and/or treating damage to the cavernous nerve of the penis.
  • compositions described in the present invention include (but are not limited to): pharmaceutical compositions, food compositions, health care compositions, dietary supplements, and the like.
  • the cell-free fat extracts of the present invention can be prepared into pharmaceutical compositions such as tablets, capsules, powders, microparticles, solutions, lozenges, jellies, creams, elixirs, suspensions, Dosage forms such as tinctures, poultices, liniments, lotions, and aerosols.
  • Pharmaceutical compositions can be prepared by generally known preparation techniques, and suitable pharmaceutical additives can be added to the medicament.
  • composition of the present invention may also include a pharmaceutically, food, health product or dietary acceptable carrier.
  • “Pharmaceutically, food, nutraceutical or dietary acceptable carrier” means: one or more compatible solid or liquid filler or gel substances, which are suitable for human use and must be of sufficient purity and sufficiently low toxicity.
  • “Compatibility” as used herein means that the components of the composition can be admixed with the compounds of the present invention and with each other without significantly reducing the efficacy of the compounds.
  • acceptable carrier moieties are cellulose and its derivatives (such as sodium carboxymethyl cellulose, sodium ethyl cellulose, cellulose acetate, etc.) , gelatin, talc, solid lubricants (such as stearic acid, magnesium stearate), calcium sulfate, vegetable oils (such as soybean oil, sesame oil, peanut oil, olive oil, etc.), polyols (such as propylene glycol, glycerin, mannitol, sorbitol) etc.), emulsifiers (such as ), wetting agents (such as sodium lauryl sulfate), colorants, flavors, stabilizers, antioxidants, preservatives, pyrogen-free water, etc.
  • cellulose and its derivatives such as sodium carboxymethyl cellulose, sodium ethyl cellulose, cellulose acetate, etc.
  • gelatin such as sodium carboxymethyl cellulose, sodium ethyl cellulose, cellulose acetate, etc.
  • the mode of administration of the composition of the present invention is not particularly limited, and representative modes of administration include (but are not limited to): oral, parenteral (intravenous, intramuscular), topical, and preferred modes of administration are oral administration and injection.
  • the injection administration is a corpus cavernosum injection formulation.
  • the dosage form of the composition or preparation of the present invention is an oral preparation, an external preparation or an injection preparation.
  • solid dosage forms for oral administration or administration include capsules, tablets, pills, powders and granules.
  • the active compound is mixed with at least one conventional inert excipient (or carrier), such as sodium citrate or dicalcium phosphate, or with (a) fillers or compatibilizers, for example, starch, lactose, sucrose, glucose, mannitol and silicic acid; (b) binders such as, for example, hydroxymethylcellulose, alginate, gelatin, polyvinylpyrrolidone, sucrose and acacia; (c) humectants, For example, glycerol; (d) disintegrants, such as agar, calcium carbonate, potato or tapioca starch, alginic acid, certain complex silicates, and sodium carbonate; (e) slow solvents, such as paraffin; (f) Absorption accelerators such as sodium citrate
  • Solid dosage forms such as tablets, dragees, capsules, pills and granules can be prepared using coatings and shell materials, such as enteric coatings and other materials well known in the art. They may contain opacifiers.
  • Liquid dosage forms for oral administration or administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups or tinctures.
  • liquid dosage forms may contain inert diluents conventionally employed in the art, such as water or other solvents, solubilizers and emulsifiers, for example, ethanol, isopropanol, ethyl carbonate, ethyl acetate, propylene glycol, 1 , 3-butanediol, dimethylformamide and oils, especially cottonseed oil, peanut oil, corn germ oil, olive oil, castor oil and sesame oil or mixtures of these substances, and the like.
  • inert diluents conventionally employed in the art, such as water or other solvents, solubilizers and emulsifiers, for example, ethanol, isopropanol, ethyl carbonate, ethyl acetate, propylene glycol, 1 , 3-butanediol, di
  • compositions can also contain adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring and perfuming agents.
  • adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring and perfuming agents.
  • Suspensions in addition to the active ingredient, may contain suspending agents such as ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum methoxide and agar, or mixtures of these substances and the like.
  • suspending agents such as ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum methoxide and agar, or mixtures of these substances and the like.
  • compositions for parenteral injection may comprise physiologically acceptable sterile aqueous or anhydrous solutions, dispersions, suspensions or emulsions, and sterile powders for reconstitution into sterile injectable solutions or dispersions.
  • Suitable aqueous and non-aqueous carriers, diluents, solvents or excipients include water, ethanol, polyols and suitable mixtures thereof.
  • Dosage forms for topical administration or administration of the compounds of this invention include ointments, powders, patches, sprays and inhalants.
  • the active ingredient is mixed under sterile conditions with a physiologically acceptable carrier and any preservatives, buffers, or propellants that may be required if necessary.
  • the cell-free adipose extract of the present invention may be administered or administered alone, or in combination with other drugs for preventing and/or treating fatty liver and/or its complications.
  • a safe and effective amount of the cell-free fat extract of the present invention is suitable for human or non-human animals (such as rats, mice, dogs, cats, cows, chickens, ducks, etc.) in need of treatment, wherein the administration
  • the current dose is the effective dose that can be considered as acceptable in pharmacy, food or health care products.
  • the term "safe and effective amount” refers to an amount that produces function or activity in humans and/or animals and is acceptable to humans and/or animals. Those of ordinary skill in the art should understand that the "safe and effective amount” may vary with the form of the pharmaceutical composition, the route of administration, the excipients of the drug used, the severity of the disease, and the combination with other drugs, etc. different.
  • the daily dosage is usually 0.1 to 1000 mg, preferably 1 to 600 mg, and more preferably 2 to 300 mg.
  • the specific dosage should also take into account the route of administration, the patient's health and other factors, which are all within the skill of the skilled physician.
  • the present invention finds for the first time that the acellular fat extract has an excellent improvement effect on erectile dysfunction and cavernosal nerve injury, and can be used for the treatment of erectile dysfunction caused by injury to the cavernosal nerve of the penis.
  • the cell-free fat extract of the present invention is a cell-free component that can avoid cell-related problems in clinical applications, including, for example, genetic stability after cell processing, cell viability and survival rate after injection, The multiple administration and storage of cells, and the immunogenicity of cells when allogeneic fat is used, the cell-free fat extract of the present invention has higher safety and lower side effects as a preparation for the prevention and treatment of erectile dysfunction.
  • Adipose tissue was obtained from 6 healthy women who underwent conventional liposuction, with an average age of 31 years (24-36 years). After local injection of tumescent fluid anesthesia, a 3mm liposuction cannula with a large lateral hole (2mm x 7mm) was used to connect a 20mL syringe, and radial suction was performed under artificial negative pressure. Rinse 3 times with normal saline.
  • the middle layer ie, the fat layer containing adipocytes
  • the mechanically emulsified fat mixture was placed in a -80°C refrigerator for freezing, and then thawed in a 37°C water bath. After a single freeze-thaw cycle, the thawed fat mixture was centrifuged at 1200g at 4°C for 5 minutes to obtain fractions.
  • the layered mixture is divided into 4 layers, the first layer is the oil layer, the second layer is the residual adipose tissue layer, the third layer is the liquid layer, and the fourth layer is the cell/tissue debris precipitation layer, remove the oil layer and For the residual adipose tissue layer, the liquid layer is sucked, and the contamination of the cell/tissue debris sediment layer is avoided during the sucking process, so as to obtain the initial fat extraction solution.
  • the content of cytokines including IGF-1, BDNF, GDNF, bFGF, VEGF, TGF-1, HGF and PDGF, was detected by ELISA immunosorbent assay kit.
  • the average concentrations of 6 samples were as follows: IGF-1 (9840.6pg/ml), BDNF (1764.5pg/ml), GDNF (1831.9pg/ml), bFGF (242.3pg/ml), VEGF (202.9pg/ml), TGF- ⁇ 1 (954.5 pg/ml), HGF (898.4 pg/ml) and PDGF (179.9 pg/ml).
  • CNI-ED cavernous nerve injury
  • 10-12-week-old male Sprague-Dawley rats (300-350 g) were selected for the experiment, acclimated to the environment for a week in advance, injected intraperitoneally with chloral hydrate, and fixed on a temperature-controlled flat plate in a supine position after losing consciousness.
  • the skin and subcutaneous tissue were incised along the ventral midline, the bladder was lifted with forceps, the prostate was exposed, and the cavernous nerve (CN) was carefully isolated in the posterolateral lobe of the prostate.
  • the corpus cavernosum was clamped with micro-tweezers for 30 s and then released, and then clamped for 30 s at an interval of 30 s, and then the abdominal cavity was closed to construct the corpus cavernosum.
  • Neuroinjury-induced erectile dysfunction (CNI-ED) rat model After the skin and subcutaneous tissue of the rats in the sham operation group were surgically incised, the abdomen was directly closed and the skin was sutured without any treatment. The sham operation group was used as the blank control group.
  • CNI-ED model rats were randomly divided into model control group, CEFFE group and adipose-derived stem cell (ASCs) group.
  • the administration methods of rats in each group were as follows:
  • Blank control group 200 ⁇ l of normal saline was locally injected into the bilateral corpus cavernosum of SD rats;
  • Model control group 200 ⁇ l of normal saline was locally injected into the bilateral corpus cavernosum of SD rats;
  • CEFFE group 200 ⁇ l CEFFE was locally injected into the bilateral corpus cavernosum of SD rats;
  • Adipose-derived stem cells (ASCs) group 200 ⁇ l of adipose-derived stem cells (1*106/ml cells) were locally injected into the bilateral corpus cavernosum of SD rats.
  • the erectile function of rats was assessed by electrical stimulation of the cavernosal nerve of the penis to record intracavernous pressure (ICP).
  • ICP intracavernous pressure
  • the rats were anesthetized as before, the corpus cavernosum nerve was found, the corpus cavernosum was peeled off and fully exposed, a 25G needle was punctured into the left corpus cavernosum, and the puncture needle was fixed.
  • the left carotid artery was exposed through the midline incision in the neck, the carotid artery was punctured with a 23G needle, and the needle was fixed.
  • the needle connecting the corpus cavernosum and the carotid artery is connected to the multi-channel physiological recording system through a catheter, heparin solution is perfused into the catheter, and a bipolar electrode is placed to hook the cavernosal nerve of the penis. Electrical stimulation was performed, and the intracavernous pressure (ICP) and mean arterial pressure (MAP) were recorded at the same time. Each side of the cavernosal nerve was stimulated 3 times, and the corpus cavernosum pressure (ICP) and mean arterial pressure (MAP) were recorded, and the ICP and mean arterial pressure (MAP) were recorded. The ratio of MAP (ICP/MAP) was used to assess erectile function in rats.
  • ICP intracavernous pressure
  • MAP mean arterial pressure
  • the ICP/MAP pressure measurement results of the rats in the 4 groups after operation are shown in Figure 1. It can be seen from Figure 1 that the corpus cavernosum pressure (ICP)/mean arterial pressure (MAP) of the model control group was significantly lower than that of the blank. The control group showed that the penile cavernous nerve injury-induced erectile dysfunction (CNI-ED) model was successfully constructed. The ICP/MAP in the CEFFE group and the ASCs group was significantly higher than that in the model control group, and there was no significant difference between the two groups, indicating that both CEFFE and ASCs could significantly improve the erectile function of CNI-ED.
  • ICP corpus cavernosum pressure
  • MAP mean arterial pressure
  • CNI-ED penile cavernous nerve injury-induced erectile dysfunction

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Organic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

提供一种无细胞脂肪提取物用于制备组合物或制剂的用途，所述组合物或制剂用于(i)预防和/或治疗勃起功能障碍；和/或(ii)预防和/或治疗阴茎海绵体神经损伤。

Description

〈无细胞脂肪提取物对勃起功能障碍的治疗用途〉 技术领域
本发明涉及药物领域，具体涉及无细胞脂肪提取物对无细胞脂肪提取物对勃起功能障碍的治疗用途。
背景技术
男性勃起功能障碍(ED)是指男性持续性或反复发作的难以达到和维持阴茎勃起，进而无法完成性交和满意性活动的病理现象。
阴茎海绵体神经(Cavernous nerves,CN)是诱导阴茎勃起的主要神经，各种原因的CN损伤均会造成神经性阴茎勃起功能障碍(NED)。例如盆腔手术如前列腺癌根治手术等极易损伤CN，从而引起术后NED。然而，现有技术缺乏对阴茎海绵体神经损伤导致的勃起功能障碍缺乏有效的治疗药物，从而限制了对勃起功能障碍患者的有效治疗。
因此，本领域需要开发一种能够有效治疗阴茎海绵体神经损伤导致的勃起功能障碍的药物。
发明内容
本发明的目在于提供一种无细胞脂肪提取物在预防和/或治疗勃起功能障碍和阴茎海绵体神经损伤方面中的用途。
本发明第一方面，提供一种无细胞脂肪提取物的用途，用于制备组合物或制剂，所述组合物或制剂用于选自下组的一种或多种用途：(i)预防和/或治疗勃起功能障碍；(ii)预防和/或治疗阴茎海绵体神经损伤。
在另一优选例中，所述的勃起功能障碍为男性勃起功能障碍。
在另一优选例中，所述的勃起功能障碍包括阴茎海绵体神经损伤引起的勃起功能障碍。
在另一优选例中，所述的无细胞脂肪提取物为从人或非人哺乳动物中的脂肪中提取制备获得的无细胞脂肪提取物。
在另一优选例中，所述的非人哺乳动物为猴、猩猩、牛、猪、狗、羊、鼠或兔。
在另一优选例中，所述的组合物或制剂包括药物组合物或制剂、食品组合物或制剂、保健品组合物或制剂或膳食补充剂。
在另一优选例中，所述的组合物或制剂还包括药学上、食品上、保健品或膳食上可接受的载体。
在另一优选例中，所述的组合物或制剂的剂型为口服制剂、外用制剂或注射 制剂。
在另一优选例中，所述的注射制剂为静脉注射剂或肌肉注射剂。
在另一优选例中，所述的注射制剂为阴茎海绵体注射制剂。
在另一优选例中，所述组合物或制剂的剂型为固体剂型、半固体剂型、或液体剂型，如溶液、凝胶、膏霜、乳液、膏剂、霜剂、糊剂、饼、粉剂、贴剂等。
在另一优选例中，所述组合物或制剂的剂型为粉剂、颗粒剂、胶囊剂、注射剂、酊剂、口服液、片剂或含片。
在另一优选例中，所述的组合物或制剂通过外用、局部、或注射方式施用。
在另一优选例中，所述的注射方式为阴茎海绵体注射。
在另一优选例中，所述无细胞脂肪提取物不含有细胞且不含有脂滴。
在另一优选例中，所述脂滴为脂肪细胞破碎后释放的油滴。
在另一优选例中，所述“不含有脂滴”指所述无细胞脂肪提取物中，油滴体积占总液体百分比小于1％，优选地小于0.5％，更优选地小于0.1％。
在另一优选例中，所述细胞选自下组：内皮细胞、脂肪干细胞、巨噬血细胞、基质细胞。
在另一优选例中，所述“无细胞”指1ml无细胞脂肪提取物中的细胞平均数量≤1个，优选地≤0.5个，更佳地≤0.1个，或为0个。
在另一优选例中，所述无细胞脂肪提取物为天然获得的无添加成分的纳米脂肪提取物。
在另一优选例中，所述“无添加成分的”指除漂洗步骤外，在所述脂肪提取物的制备过程中未添加任何溶液、溶剂、小分子、化学制剂、和生物添加剂。
在另一优选例中，所述种无细胞脂肪提取物是通过将脂肪组织经过乳化后离心制备获得。
在另一优选例中，所述的无细胞脂肪提取物含有一种或多种选自下组的组分：IGF-1、BDNF、GDNF、TGF-β1、HGF、bFGF、VEGF、TGF-β1、PDGF、EGF、NT-3、GH、G-CSF，或其组合。
在另一优选例中，所述的种无细胞脂肪提取物含有但不限于一种或多种选自下组的组分：IGF-1、BDNF、GDNF、bFGF、VEGF、TGF-β1、HGF、PDGF，或其组合。
在另一优选例中，所述的无细胞脂肪提取物为无细胞脂肪提取液。
在另一优选例中，在所述的无细胞脂肪提取物中，所述的IGF-1的浓度为5000-30000pg/ml，较佳地6000-20000pg/ml，更佳地7000-15000pg/ml，更佳地8000-12000pg/ml，更佳地9000-11000pg/ml，更佳地9500-10500pg/ml。
在另一优选例中，在所述的无细胞脂肪提取物中，所述的BDNF的浓度为800-5000pg/ml，较佳地1000-4000pg/ml，更佳地1200-2500pg/ml，更佳地1400-2000pg/ml，更佳地1600-2000pg/ml，更佳地1700-1850pg/ml。
在另一优选例中，在所述的无细胞脂肪提取物中，所述的GDNF的浓度为800-5000pg/ml，较佳地1000-4000pg/ml，更佳地1200-2500pg/ml，更佳地1400-2000pg/ml，更佳地1600-2000pg/ml，更佳地1700-1900pg/ml。
在另一优选例中，在所述的无细胞脂肪提取物中，所述的bFGF的浓度为50-600pg/ml，较佳地100-500pg/ml，更佳地120-400pg/ml，更佳地150-300pg/ml，更佳地200-280pg/ml，更佳地220-260pg/ml。
在另一优选例中，在所述的无细胞脂肪提取物中，所述的VEGF的浓度为50-500pg/ml，较佳地100-400pg/ml，更佳地120-300pg/ml，更佳地150-250pg/ml，更佳地170-230pg/ml，更佳地190-210pg/ml。
在另一优选例中，在所述的无细胞脂肪提取物中，所述的TGF-β1的浓度为200-3000pg/ml，较佳地400-2000pg/ml，更佳地600-1500pg/ml，更佳地800-1200pg/ml，更佳地800-1100pg/ml，更佳地900-1000pg/ml。
在另一优选例中，在所述的无细胞脂肪提取物中，所述的HGF的浓度为200-3000pg/ml，较佳地400-2000pg/ml，更佳地600-1500pg/ml，更佳地600-1200pg/ml，更佳地800-1000pg/ml，更佳地850-950pg/ml。
在另一优选例中，在所述的无细胞脂肪提取物中，所述的PDGF的浓度为50-600pg/ml，较佳地80-400pg/ml，更佳地100-300pg/ml，更佳地140-220pg/ml，更佳地160-200pg/ml，更佳地170-190pg/ml。
在另一优选例中，所述的IGF-1与VEGF的重量比为20-100：1，较佳地30-70：1，更佳地40-60：1，最佳地45-55：1。
在另一优选例中，所述的BDNF与VEGF的重量比为2-20：1，较佳地4-15：1，更佳地6-12：1，最佳地8-9.5：1。
在另一优选例中，所述的GDNF与VEGF的重量比为2-20：1，较佳地4-15：1，更佳地6-12：1，最佳地8.5-9.5：1。
在另一优选例中，所述的bFGF与VEGF的重量比为0.2-8：1，较佳地0.5-5：1，更佳地0.6-2：1，更佳地0.8-1.6：1，最佳地1-1.5：1。
在另一优选例中，所述的TGF-β1与VEGF的重量比为1-20：1，较佳地1-15：1，更佳地1-10：1，更佳地2-8：1，更佳地4-6：1。
在另一优选例中，所述的HGF与VEGF的重量比为1-20：1，较佳地1-15：1，更佳地1-10：1，更佳地2-8：1，更佳地4-5.5：1。
在另一优选例中，所述的PDGF与VEGF的重量比为0.1-3：1，较佳地0.2-2：1，更佳地0.4-1.5：1，最佳地0.7-1.2：1。
在另一优选例中，所述的无细胞脂肪提取物通过以下方法制备：
(1)提供一脂肪组织原料，将所述脂肪组织原料破碎，并进行漂洗(如用生理盐水)，从而获得经漂洗的脂肪组织；
(2)对所述经漂洗后的脂肪组织进行离心，获得分层的混合物；
(3)对所述分层的混合物，去除上层油层和下层水层，收集中间层(即含脂肪细胞的脂肪层)；
(4)对所述中间层进行乳化，获得乳化的脂肪混合物(也称为纳米脂肪)；
(5)将所述乳化的脂肪混合物通过离心处理，从而获得中间液体层，即为脂肪初提物；和
(6)对所述脂肪初提物进行过滤和除菌，从而获得无细胞的脂肪提取物。
本发明第二方面，提供一种制备无细胞脂肪提取物的方法，所述的方法包括步骤：
(1)提供一脂肪组织原料，将所述脂肪组织原料破碎，并进行漂洗(如用生理盐水)，从而获得经漂洗的脂肪组织；
(2)对所述经漂洗后的脂肪组织进行离心，获得分层的混合物；
(3)对所述分层的混合物，去除上层油层和下层水层，收集中间层(即含脂肪细胞的脂肪层)；
(4)对所述中间层进行乳化，获得乳化的脂肪混合物(也称为纳米脂肪)；
(5)将所述乳化的脂肪混合物通过离心处理，从而获得中间液体层，即为脂肪初提物；和
(6)对所述脂肪初提物进行过滤和除菌，从而获得无细胞的脂肪提取物。
在另一优选例中，所述的无细胞脂肪提取物如本发明第一方面所述。
在另一优选例中，所述的步骤(2)中，所述离心在800-2500g下离心，较佳地800-2000g，更佳地1000-1500g，最佳地1100-1300g。
在另一优选例中，所述的步骤(2)中，所述离心的时间为1-15min，较佳地1-10min，更佳地1-8min，最佳地1-5min。
在另一优选例中，所述的离心的温度为2-6℃。
在另一优选例中，所述的步骤(4)中，所述的乳化为机械乳化。
在另一优选例中，所述机械乳化为经注射器反复吹打(如吹打20-200次，较佳地20-150次，更佳地20-100次，更佳地30-50次)进行机械乳化。
在另一优选例中，所述的吹打的方式为2个10ml注射针筒连接三通管反复匀速推打。
在另一优选例中，，所述的步骤(4)中，所述乳化为通过组织匀浆机打碎的方法。
在另一优选例中，所述的步骤(5)中，在将所述乳化的脂肪混合物通过离心处理前，还包括对所述乳化的脂肪混合物冷冻后解冻处理。
在另一优选例中，冷冻后解冻处理后，将解冻后的混合物用于离心。
在另一优选例中，所述的冷冻的温度为-50℃至-120℃，较佳地-60℃至-100℃，更佳地-70℃至-90℃。
在另一优选例中，所述的解冻的温度为20-40℃，较佳地25-40℃，更佳地37℃。
在另一优选例中，所述的冷冻后解冻的循环次数为1-5次(优选为1、2、3或4次)。
在另一优选例中，所述的步骤(5)中，离心后，所述乳化的脂肪混合物分层4层，第一层为油层，第二层为残余脂肪组织层，第三层为液体层(即为中间液体层)，第四层为细胞/组织碎片沉淀层。
在另一优选例中，所述的步骤(5)中，所述离心在800-2500g下离心，较佳地800-2000g，更佳地1000-1500g，最佳地1100-1300g。
在另一优选例中，所述的步骤(5)中，所述离心的时间为1-15min，较佳地1-10min，更佳地2-8min，最佳地3-7min。
在另一优选例中，所述的离心的温度为2-6℃。
在另一优选例中，所述的步骤(5)中，第一层、第二层、第三层和第四层从上到下依次排列。
在另一优选例中，所述的步骤(5)中，所述的中间液体层为透明或基本透明层。
在另一优选例中，所述的步骤(6)中，所述的过滤包能够将脂肪初提物中的脂肪细胞除去。
在另一优选例中，所述的步骤(6)中，所述的过滤和除菌是通过滤器(如0.22μm微孔滤膜)进行。
在另一优选例中，所述的过滤器为微孔滤膜过滤器。
在另一优选例中，所述的微孔滤膜的孔径大小为0.05-0.8μm，较佳地0.1-0.5μm，更佳地0.1-0.4μm，更佳地0.15-0.3μm，更佳地0.2-0.25μm，最佳地0.22μm。
在另一优选例中，所述的步骤(6)中，所述的过滤和除菌是先通过可滤去细胞的第一过滤器，然后再通过可滤去病原体(如细菌)的第二滤器(如0.22μm的滤器)进行的。
在另一优选例中，所述的步骤(6)中，还包括对所述脂肪提取物进行分装，形成分装的产品。(所述分装后的提取物可于-20℃保存待用；可低温(如-4℃)或常温解冻后直接使用，或解冻后置于低温(如4℃)保存一段时间，然后使用)。
本发明第三方面，提供一种无细胞脂肪提取物，所述的无细胞脂肪提取物通过如本发明第二方面所述的方法制备获得。
本发明第四方面，提供一种组合物或制剂，所述的组合物或制剂包含(a)如本发明第三方面所述的无细胞脂肪提取物；和(b)药学上、食品上、保健品或膳食 上可接受的载体或赋形剂。
在另一优选例中，所述的组合物为药物组合物、食品组合物、保健品组合物或膳食补充剂。
在另一优选例中，所述的组合物或制剂的剂型为口服制剂、外用制剂或注射制剂。
在另一优选例中，所述组合物或制剂的剂型为粉剂、颗粒剂、胶囊剂、注射剂、酊剂、口服液、片剂或含片。
在另一优选例中，所述的注射剂为静脉注射剂或肌肉注射剂。
在另一优选例中，所述组合物或制剂的剂型为固体剂型、半固体剂型、或液体剂型，如溶液、凝胶、膏霜、乳液、膏剂、霜剂、糊剂、饼、粉剂、贴剂等。
在另一优选例中，在所述组合物或制剂中，无细胞脂肪提取物的质量百分比为5wt％，较佳地1-20wt％，以合物或制剂的总重量计。
本发明第五方面，提供一种制备如本发明第四方面所述的组合物或制剂的方法，所述的方法包括步骤：将如本发明第三方面所述的无细胞脂肪提取物与药学上、食品上、保健品或膳食上可接受的载体或赋形剂混合，从而形成组合物或制剂。
本发明第六方面，提供一种(i)预防和/或治疗勃起功能障碍；和/或(ii)预防和/或治疗阴茎海绵体神经损伤的方法，对需要的对象施用如本发明第三方面所述的的无细胞脂肪提取物。
在另一优选例中，所述的对象为人或非人哺乳动物。
在另一优选例中，所述非人哺乳动物包括啮齿动物，如大鼠、小鼠。
在另一优选例中，所述的施用方式为口服、外用或注射施用。
在另一优选例中，所述的施用为阴茎海绵体注射施用。
应理解，在本发明范围内中，本发明的上述各技术特征和在下文(如实施例)中具体描述的各技术特征之间都可以互相组合，从而构成新的或优选的技术方案。限于篇幅，在此不再一一累述。
附图说明
图1为各组大鼠的ICP/MAP压力测定结果。
具体实施方式
本发明人经过广泛而深入的研究，首次开发了无细胞脂肪提取物对勃起功能障碍具有优异的治疗作用。本发明实施例研究表明，本发明所述的无细胞脂肪提 取液对阴茎海绵体神经损伤性具有优异的改善效果，且对阴茎海绵体神经损伤引起的勃起功能障碍具有优异的治疗效果。在此基础上完成了本发明。
术语
除非另有定义，否则本文中所用的所有技术和科学术语的含义与本发明所属领域普通技术人员普遍理解的含义相同。
如本文所用，术语“包括”、“包含”与“含有”可互换使用，不仅包括开放式定义，还包括半封闭式、和封闭式定义。换言之，所述术语包括了“由……构成”、“基本上由……构成”。
在本发明中，术语“预防”表示预防疾病和/或它的附随症状的发作或者保护对象免于获得疾病的方法。本文中使用的"预防"还包括延迟疾病和/或它的附随症状的发作和降低对象的得病的风险。
本发明所述的“治疗”包括延缓和终止疾病的进展，或消除疾病，并不需要100％抑制、消灭和逆转。在一些实施方案中，与不存在本发明所述的无细胞脂肪提取物观相比，本发明所述无细胞脂肪提取物减轻、抑制和/或逆转了勃起功能障碍例如至少约10％、至少约30％、至少约50％、或至少约80％。
如文本所用，术语“IGF-1”称为胰岛素样生长因子1(insulin-like growth factors-1)。
如文本所用，术语“BDNF”称为脑源性神经营养因子(brain-derived neurotrophic factor，BDNF)。
如文本所用，术语“GDNF”称为胶质细胞源性神经营养因子(glialcellline-derivedneurotrophicfactor)。
如文本所用，术语“bFGF”称为碱性成纤维细胞生长因子(basic fibroblast growth factor)。
如文本所用，术语“VEGF”称为血管内皮生长因子(vascular endothelial growth factor)。
如文本所用，术语“TGF-β1”称为转化生长因子-β1(transforming growth factor-β1)。
如文本所用，术语“HGF”称为肝细胞生长因子
如文本所用，术语“PDGF”称为血小板衍生生长因子(Platelet derived growth factor)
如文本所用，术语“EGF”称为表皮细胞生长因子(Epidermal Growth Factor)
如文本所用，术语“NT-3”称为神经营养因子3(neurotrophins-3)。
如文本所用，术语“GH”称为生长激素(Growth Hormone)。
如文本所用，术语“G-CSF”称为粒细胞集落刺激因子(granulocyte colony stimulating factor)。
无细胞脂肪提取物(Cell free fat extract,CEFFE)及其制备方法
如本文所用，术语“本发明的无细胞脂肪提取物”、“本发明提取物”、“本发明的脂肪提取物”等可互换使用，指在脂肪提取物制备过程中(除漂洗步骤外)未添加任何溶液、溶剂、小分子、化学制剂、和生物添加剂所制备的源自脂肪组织的提取物(或提取液)。一种典型的制备本发明提取物的方法如上本发明第二方面中所述。此外，应理解，虽然本发明提取物在制备过程中不必添加任何添加剂(或添加成分)，但是也可以添加一些或少量的对本发明提取物的活性无负面或不利影响的安全的物质(如少量水)。
本发明的无细胞脂肪提取物可来源于人类脂肪组织，它是通过离心后除去油和细胞/细胞外基质部分而从纳米脂肪中提纯出来的，是一种无细胞、易于制备、富含各种生长因子的液体。
在本发明的一个优选例中，所述的无细胞脂肪提取物为无细胞脂肪提取液。
在本发明所述的无细胞脂肪提取物，可以包括多种细胞因子。代表性地，所述的无细胞脂肪提取物包括IGF-1、BDNF、GDNF、TGF-β、HGF、bFGF、VEGF、TGF-β1、PDGF、EGF、NT-3、GH和G-CSF中的一种或多种。
在另一优选例中，在所述的无细胞脂肪提取物中，所述的IGF-1的浓度为5000-30000pg/ml，较佳地6000-20000pg/ml，更佳地7000-15000pg/ml，更佳地8000-12000pg/ml，更佳地9000-11000pg/ml，更佳地9500-10500pg/ml。
在另一优选例中，在所述的无细胞脂肪提取物中，所述的BDNF的浓度为800-5000pg/ml，较佳地1000-4000pg/ml，更佳地1200-2500pg/ml，更佳地1400-2000pg/ml，更佳地1600-2000pg/ml，更佳地1700-1850pg/ml。
在另一优选例中，在所述的无细胞脂肪提取物中，所述的GDNF的浓度为800-5000pg/ml，较佳地1000-4000pg/ml，更佳地1200-2500pg/ml，更佳地1400-2000pg/ml，更佳地1600-2000pg/ml，更佳地1700-1900pg/ml。
在另一优选例中，在所述的无细胞脂肪提取物中，所述的bFGF的浓度为50-600pg/ml，较佳地100-500pg/ml，更佳地120-400pg/ml，更佳地150-300pg/ml，更佳地200-280pg/ml，更佳地220-260pg/ml。
在另一优选例中，在所述的无细胞脂肪提取物中，所述的VEGF的浓度为50-500pg/ml，较佳地100-400pg/ml，更佳地120-300pg/ml，更佳地150-250pg/ml，更佳地170-230pg/ml，更佳地190-210pg/ml。
在另一优选例中，在所述的无细胞脂肪提取物中，所述的TGF-β1的浓度为200-3000pg/ml，较佳地400-2000pg/ml，更佳地600-1500pg/ml，更佳地800-1200pg/ml，更佳地800-1100pg/ml，更佳地900-1000pg/ml。
在另一优选例中，在所述的无细胞脂肪提取物中，所述的HGF的浓度为200-3000pg/ml，较佳地400-2000pg/ml，更佳地600-1500pg/ml，更佳地600-1200 pg/ml，更佳地800-1000pg/ml，更佳地850-950pg/ml。
在另一优选例中，在所述的无细胞脂肪提取物中，所述的PDGF的浓度为50-600pg/ml，较佳地80-400pg/ml，更佳地100-300pg/ml，更佳地140-220pg/ml，更佳地160-200pg/ml，更佳地170-190pg/ml。
在另一优选例中，所述的IGF-1与VEGF的重量比为20-100：1，较佳地30-70：1，更佳地40-60：1，最佳地45-55：1。
在另一优选例中，所述的BDNF与VEGF的重量比为2-20：1，较佳地4-15：1，更佳地6-12：1，最佳地8-9.5：1。
在另一优选例中，所述的GDNF与VEGF的重量比为2-20：1，较佳地4-15：1，更佳地6-12：1，最佳地8.5-9.5：1。
在另一优选例中，所述的bFGF与VEGF的重量比为0.2-8：1，较佳地0.5-5：1，更佳地0.6-2：1，更佳地0.8-1.6：1，最佳地1-1.5：1。
在另一优选例中，所述的TGF-β1与VEGF的重量比为1-20：1，较佳地1-15：1，更佳地1-10：1，更佳地2-8：1，更佳地4-6：1。
在另一优选例中，所述的HGF与VEGF的重量比为1-20：1，较佳地1-15：1，更佳地1-10：1，更佳地2-8：1，更佳地4-5.5：1。
在另一优选例中，所述的PDGF与VEGF的重量比为0.1-3：1，较佳地0.2-2：1，更佳地0.4-1.5：1，最佳地0.7-1.2：1。
优选地，本发明所述的无细胞脂肪提取物通过如上述本发明第二方面所述的方法制备获得。
代表性地，本发明所述的无细胞脂肪提取物通过以下方法制备：
(1)提供一脂肪组织原料，将所述脂肪组织原料破碎，并进行漂洗(如用生理盐水)，从而获得经漂洗的脂肪组织；
(2)对所述经漂洗后的脂肪组织进行离心，获得分层的混合物；
(3)对所述分层的混合物，去除上层油层和下层水层，收集中间层(即含脂肪细胞的脂肪层)；
(4)对所述中间层进行乳化，获得乳化的脂肪混合物(也称为纳米脂肪)；
(5)将所述乳化的脂肪混合物通过离心处理，从而获得中间液体层，即为脂肪初提物；和
(6)对所述脂肪初提物进行过滤和除菌，从而获得无细胞的脂肪提取物。
在另一优选例中，所述的步骤(2)中，所述离心在800-2500g下离心，较佳地800-2000g，更佳地1000-1500g，最佳地1100-1300g。
在另一优选例中，所述的步骤(2)中，所述离心的时间为1-15min，较佳地1-10min，更佳地1-8min，最佳地1-5min。
在另一优选例中，所述的步骤(4)中，所述的乳化为机械乳化。
在另一优选例中，所述机械乳化为经注射器反复吹打(如吹打20-200次，较 佳地20-150次，更佳地20-100次，更佳地30-50次)进行机械乳化。
在另一优选例中，所述的吹打的方式为2个10ml注射针筒连接三通管反复匀速推打。
在另一优选例中，所述的步骤(4)中，所述乳化为通过组织匀浆机打碎的方法。
在另一优选例中，所述的步骤(5)中，在将所述乳化的脂肪混合物通过离心处理前，还包括对所述乳化的脂肪混合物冷冻后解冻处理。
在另一优选例中，冷冻后解冻处理后，将解冻后的混合物用于离心。
在另一优选例中，所述的冷冻的温度为-50℃至-120℃，较佳地-60℃至-100℃，更佳地-70℃至-90℃。
在另一优选例中，所述的解冻的温度为20-40℃，较佳地25-40℃，更佳地37℃。
在另一优选例中，所述的冷冻后解冻的循环次数为1-5次(优选为1、2、3或4次)。
在另一优选例中，所述的步骤(5)中，离心后，所述乳化的脂肪混合物分层4层，第一层为油层，第二层为残余脂肪组织层，第三层为液体层(即为中间液体层)，第四层为细胞/组织碎片沉淀层。
在另一优选例中，所述的步骤(5)中，所述离心在800-2500g下离心，较佳地800-2000g，更佳地1000-1500g，最佳地1100-1300g。
在另一优选例中，所述的步骤(5)中，所述离心的时间为1-15min，较佳地1-10min，更佳地2-8min，最佳地3-7min。
在另一优选例中，所述的步骤(5)中，第一层、第二层、第三层和第四层从上到下依次排列。
在另一优选例中，所述的步骤(5)中，所述的中间液体层为透明或基本透明层。
在另一优选例中，所述的步骤(6)中，所述的过滤包能够将脂肪初提物中的脂肪细胞除去。
在另一优选例中，所述的步骤(6)中，所述的过滤和除菌是通过滤器(如0.22μm微孔滤膜)进行。
在另一优选例中，所述的过滤器为微孔滤膜过滤器。
在另一优选例中，所述的微孔滤膜的孔径大小为0.05-0.8μm，较佳地0.1-0.5μm，更佳地0.1-0.4μm，更佳地0.15-0.3μm，更佳地0.2-0.25μm，最佳地0.22μm。
在另一优选例中，所述的步骤(6)中，所述的过滤和除菌是先通过可滤去细胞的第一过滤器，然后再通过可滤去病原体(如细菌)的第二滤器(如0.22μm的滤器)进行的。
在另一优选例中，所述的步骤(6)中，还包括对所述脂肪提取物进行分装，形成分装的产品。(所述分装后的提取物可于-20℃保存待用；可低温(如-4℃)或常温解冻后直接使用，或解冻后置于低温(如4℃)保存一段时间，然后使用)。
用途
本发明提供一种无细胞脂肪提取物的用途，用于制备组合物或制剂，所述组合物或制剂用于选自下组的一种或多种用途：(i)预防和/或治疗勃起功能障碍；(ii)预防和/或治疗阴茎海绵体神经损伤。
在本发明一个优选例中，所述的勃起功能障碍为人类男性勃起功能障碍。
在本发明另一优选例中，所述的勃起功能障碍包括阴茎海绵体神经损伤引起的勃起功能障碍。本发明所述的无细胞脂肪提取物可通过预防和/或治疗阴茎海绵体神经损伤来预防和/或治疗勃起功能障碍。
组合物和施用
本发明所述的组合物包括(但并不限于)：药物组合物、食品组合物、保健组合物、膳食补充剂等。
代表性地，可将本发明的无细胞脂肪提取物制备成药物组合物，诸如片剂、胶囊、粉剂、微粒剂、溶液剂、锭剂、胶冻、乳膏制剂、醑剂、悬液、酊、泥敷剂、搽剂、洗剂、和气雾剂之类的剂型。药物组合物能够由通常已知的制备技术来制备，并且合适的药物添加剂能够被添加到该药物中。
本发明的组合物还可以包括药学上、食品上、保健品或膳食上可接受的载体。“药学上、食品上、保健品或膳食上可接受的载体”指的是：一种或多种相容性固体或液体填料或凝胶物质，它们适合于人使用，而且必须有足够的纯度和足够低的毒性。“相容性”在此指的是组合物中各组份能和本发明的化合物以及它们之间相互掺和，而不明显降低化合物的药效。药学上、食品上、保健品或膳食上可接受的载体可以接受的载体部分例子有纤维素及其衍生物(如羧甲基纤维素钠、乙基纤维素钠、纤维素乙酸酯等)、明胶、滑石、固体润滑剂(如硬脂酸、硬脂酸镁)、硫酸钙、植物油(如豆油、芝麻油、花生油、橄榄油等)、多元醇(如丙二醇、甘油、甘露醇、山梨醇等)、乳化剂(如
Figure PCTCN2021140982-appb-000001
)、润湿剂(如十二烷基硫酸钠)、着色剂、调味剂、稳定剂、抗氧化剂、防腐剂、无热原水等。
本发明组合物施用方式没有特别限制，代表性的施用方式包括(但并不限于)：口服、肠胃外(静脉内、肌肉内)、局部施用，优选的施用方式为口服施用和注射施用。例如，所述的注射施用为阴茎海绵体注射制剂。
本发明所述的组合物或制剂的剂型为口服制剂、外用制剂或注射制剂。代表性地，用于口服施用或给药的固体剂型包括胶囊剂、片剂、丸剂、散剂和颗粒剂。在这些固体剂型中，活性化合物与至少一种常规惰性赋形剂(或载体)混合，如柠 檬酸钠或磷酸二钙，或与下述成分混合：(a)填料或增容剂，例如，淀粉、乳糖、蔗糖、葡萄糖、甘露醇和硅酸；(b)粘合剂，例如，羟甲基纤维素、藻酸盐、明胶、聚乙烯基吡咯烷酮、蔗糖和阿拉伯胶；(c)保湿剂，例如，甘油；(d)崩解剂，例如，琼脂、碳酸钙、马铃薯淀粉或木薯淀粉、藻酸、某些复合硅酸盐、和碳酸钠；(e)缓溶剂，例如石蜡；(f)吸收加速剂，例如，季胺化合物；(g)润湿剂，例如鲸蜡醇和单硬脂酸甘油酯；(h)吸附剂，例如，高岭土；和(i)润滑剂，例如，滑石、硬脂酸钙、硬脂酸镁、固体聚乙二醇、十二烷基硫酸钠，或其混合物。胶囊剂、片剂和丸剂中，剂型也可包含缓冲剂。
固体剂型如片剂、糖丸、胶囊剂、丸剂和颗粒剂可采用包衣和壳材制备，如肠衣和其它本领域公知的材料。它们可包含不透明剂，。
用于口服施用或给药的液体剂型包括药学上可接受的乳液、溶液、悬浮液、糖浆或酊剂。除了活性化合物外，液体剂型可包含本领域中常规采用的惰性稀释剂，如水或其它溶剂，增溶剂和乳化剂，例知，乙醇、异丙醇、碳酸乙酯、乙酸乙酯、丙二醇、1,3-丁二醇、二甲基甲酰胺以及油，特别是棉籽油、花生油、玉米胚油、橄榄油、蓖麻油和芝麻油或这些物质的混合物等。
除了这些惰性稀释剂外，组合物也可包含助剂，如润湿剂、乳化剂和悬浮剂、甜味剂、娇味剂和香料。
除了活性成分外，悬浮液可包含悬浮剂，例如，乙氧基化异十八烷醇、聚氧乙烯山梨醇和脱水山梨醇酯、微晶纤维素、甲醇铝和琼脂或这些物质的混合物等。
用于肠胃外注射的组合物可包含生理上可接受的无菌含水或无水溶液、分散液、悬浮液或乳液，和用于重新溶解成无菌的可注射溶液或分散液的无菌粉末。适宜的含水和非水载体、稀释剂、溶剂或赋形剂包括水、乙醇、多元醇及其适宜的混合物。
用于局部施用或给药的本发明化合物的剂型包括软膏剂、散剂、贴剂、喷射剂和吸入剂。活性成分在无菌条件下与生理上可接受的载体及任何防腐剂、缓冲剂，或必要时可能需要的推进剂一起混合。
本发明无细胞脂肪提取物可以单独施用或给药，或者与其它预防和/或治疗脂肪肝和/或其并发症的药物联合施用或给药。
施用组合物时，是将安全有效量的本发明无细胞脂肪提取物适用于需要治疗的人或非人动物(如大鼠、小鼠、狗、猫、牛、鸡、鸭等)，其中施用时剂量为药学上、食品上或保健品上可接受认为的有效给药剂量。如本文所用，术语“安全有效量”，是指对人和/或动物产生功能或活性的且可被人和/或动物所接受的量。本领域的普通技术人员应该理解，所述的“安全有效量”可随着药物组合物的形式、给药途径、所用药物的辅料、疾病的严重程度以及与其他药物联合用药等情况的不同而有所不同。例如，对于60kg体重的人而言，日给药剂量通常为0.1～1000mg，优选1～600mg，更优选为2-300mg。当然，具体剂量还应考虑给药途 径、病人健康状况等因素，这些都是熟练医师技能范围之内的。
本发明的主要优点包括：
1.本发明首次发现无细胞脂肪提取物对勃起功能障碍和阴茎海绵体神经损伤具有优异的改善效果，能够用于治疗阴茎海绵体神经损伤性勃起功能障碍。
2.本发明所述的无细胞脂肪提取物是一种无细胞组分，可以避免临床应用中与细胞相关的问题，例如包括细胞加工后的遗传稳定性，注射后的细胞活性和存活率，细胞的多次给药储存，以及使用同种异体脂肪时细胞的免疫原性，本发明所述的无细胞脂肪提取物在作为制备防治勃起功能障碍中有着较高的安全性和较低副作用的优势。
下面结合具体实施例，进一步阐述本发明。应理解，这些实施例仅用于说明本发明而不用于限制本发明的范围。下列实施例中未注明具体条件的实验方法，通常按照常规条件，或按照制造厂商所建议的条件。除非另外说明，否则百分比和份数按重量计算。
实施例1
1.实验方法
1.1.无细胞脂肪提取液(CEFFE)的制备
脂肪由自愿者在获得知情同意的条件下获得。无细胞脂肪组织提取液的制备方法如下：
(1)脂肪组织获取自6名常规脂肪抽吸术的健康女性，平均年龄31岁(24-36岁)。局部注射肿胀液麻醉后，使用具有大侧孔(2mm x 7mm)的3mm吸脂抽脂套管连接20mL注射器，人工负压下放射状抽吸，将获得的脂肪直立静止，去除肿胀液后，用生理盐水漂洗3遍。
(2)取经漂洗后的脂肪组织，置于离心管中，放入离心机中以1200g 4℃离心3分钟后，获得分层的混合物。
(3)对所述分层的混合物，去除上层油层和下层水层，收集中间层(即含脂肪细胞的脂肪层)。
(4)对所述中间层，用2个10ml注射针筒连接三通管反复匀速推打30次，从而进行机械乳化，并获得经机械乳化的脂肪混合物(也称为纳米脂肪)。
(5)将所述经机械乳化的脂肪混合物置入-80℃冰箱冷冻，再进行37℃水浴解冻，单次冻融循环后，将解冻后的脂肪混合物以1200g 4℃离心5分钟，获得分层的混合物，分层的混合物共分为4层，第一层为油层，第二层为残余脂肪组织层，第三层为液体层，第四层为细胞/组织碎片沉淀层，去除油层和残余脂肪组织层，吸取液体层，吸取过程中避免细胞/组织碎片沉淀层污染，从而得到脂肪初提取液。
(6)将得到的脂肪初提取液经0.22μm滤器过滤除菌，从而灭菌并去除可能混有的活细胞，从而获得无细胞脂肪提取液(CEFFE)，分装冻存于-20℃保存，使用时4℃解冻。
对制备得到的无细胞脂肪提取液，使用ELISA免疫吸附测定试剂盒检测细胞因子含量，包括IGF-1、BDNF、GDNF、bFGF、VEGF、TGF-1、HGF和PDGF等细胞因子。6例样本检测平均浓度如下：IGF-1(9840.6pg/ml)、BDNF(1764.5pg/ml)、GDNF(1831.9pg/ml)、bFGF(242.3pg/ml)、VEGF(202.9pg/ml)、TGF-β1(954.5pg/ml)、HGF(898.4pg/ml)和PDGF(179.9pg/ml)。
1.2大鼠阴茎海绵体神经损伤性勃起功能障碍(CNI-ED)模型的建立、分组及给药
实验选择10-12周龄大小的雄性Sprague-Dawley大鼠(300-350克)，提前适应环境一周，腹腔注射水合氯醛，失去意识后仰卧位固定到温度可控平板上。沿腹正中线切开皮肤和皮下组织，用镊子提起膀胱，暴露前列腺，在前列腺后外侧叶小心分离阴茎海绵体神经(cavernous nerve，CN)。在双侧距盆大神经节(major pelvic ganglia,MPG)5毫米处，用显微镊子夹住阴茎海绵体神经30s后松开，间隔30s后再夹30s，随后关闭腹腔，从而构建阴茎海绵体神经损伤性勃起功能障碍(CNI-ED)大鼠模型。假手术组大鼠手术切开皮肤和皮下组织后，不做任何处理，直接关腹并缝合皮肤，假手术组作为空白对照组。
CNI-ED模型大鼠随机分成模型对照组、CEFFE组和脂肪来源干细胞(ASCs)组，各组大鼠给药方式如下：
空白对照组：200μl生理盐水局部注射至SD大鼠双侧阴茎海绵体；
模型对照组：200μl生理盐水局部注射至SD大鼠双侧阴茎海绵体；
CEFFE组：200μl CEFFE局部注射至SD大鼠双侧阴茎海绵体；
脂肪来源干细胞(ASCs)组：200μl脂肪来源干细胞(1*106/ml细胞)局部注射至SD大鼠双侧阴茎海绵体。
给药后4周观察各组CNI-ED大鼠的勃起功能恢复情况。
1.3勃起功能测定
采用电刺激阴茎海绵体神经记录海绵体内压(intracavernous pressure,ICP)的方法评估大鼠勃起功能。同前麻醉大鼠，找到阴茎海绵体神经，剥离并充分暴露阴茎海绵体，将25G针头穿刺入左侧海绵体内，固定穿刺针头。通过颈部正中切口，暴露左侧颈动脉，23G针头穿刺颈动脉，固定针头。将连接阴茎海绵体和颈动脉的针头通过导管与多道生理记录系统相连，导管内灌注肝素溶液，放置双极电极勾住阴茎海绵体神经，正极位于神经的近侧端，对阴茎海绵体神经进行电刺激，同时记录阴茎海绵体内压(ICP)及平均动脉压(MAP)，每侧阴茎海绵体神经 刺激3次，记录阴茎海绵体压力(ICP)及平均动脉压力(MAP)，计算ICP与MAP的比值(ICP/MAP)用于评估大鼠勃起功能。
2.结果
术后4各组大鼠的ICP/MAP压力测定结果如图1所示，从图1中可以看出，模型对照组的阴茎海绵体压力(ICP)/平均动脉压力(MAP)显著低于空白对照组，表明阴茎海绵体神经损伤性勃起功能障碍(CNI-ED)模型构建成功。CEFFE组和ASCs组ICP/MAP显著高于模型对照组，两组间无显著差异，表明CEFFE和ASCs均可以显著改善CNI-ED的阴茎勃起功能。
结论：
本申请实施例研究表明CEFFE能够改善CNI-ED大鼠的勃起功能。
在本发明提及的所有文献都在本申请中引用作为参考，就如同每一篇文献被单独引用作为参考那样。此外应理解，在阅读了本发明的上述讲授内容之后，本领域技术人员可以对本发明作各种改动或修改，这些等价形式同样落于本申请所附权利要求书所限定的范围。

Claims (10)

  1. 一种无细胞脂肪提取物的用途，其特征在于，用于制备组合物或制剂，所述组合物或制剂用于选自下组的一种或多种用途：(i)预防和/或治疗勃起功能障碍；(ii)预防和/或治疗阴茎海绵体神经损伤。
  2. 如权利要求1所述的用途，其特征在于，所述的勃起功能障碍为男性勃起功能障碍。
  3. 如权利要求1所述的用途，其特征在于，所述的勃起功能障碍包括阴茎海绵体神经损伤引起的勃起功能障碍。
  4. 如权利要求1所述的用途，其特征在于，所述的组合物或制剂包括药物组合物或制剂、食品组合物或制剂、保健品组合物或制剂或膳食补充剂。
  5. 如权利要求1所述的用途，其特征在于，所述的组合物或制剂的剂型为阴茎海绵体注射制剂。
  6. 如权利要求1所述的用途，其特征在于，所述的无细胞脂肪提取物含有一种或多种选自下组的组分：IGF-1、BDNF、GDNF、TGF-β1、HGF、bFGF、VEGF、TGF-β1、HGF、PDGF、EGF、NT-3、GH、G-CSF，或其组合。
  7. 如权利要求6所述的用途，其特征在于，所示的无细胞脂肪提取物包括选自下组的一种或多种特征：
    在所述的无细胞脂肪提取物中，所述的IGF-1的浓度为5000-30000pg/ml，较佳地6000-20000pg/ml，更佳地7000-15000pg/ml，更佳地8000-12000pg/ml，更佳地9000-11000pg/ml，更佳地9500-10500pg/ml；
    在所述的无细胞脂肪提取物中，所述的BDNF的浓度为800-5000pg/ml，较佳地1000-4000pg/ml，更佳地1200-2500pg/ml，更佳地1400-2000pg/ml，更佳地1600-2000pg/ml，更佳地1700-1850pg/ml；
    在所述的无细胞脂肪提取物中，所述的GDNF的浓度为800-5000pg/ml，较佳地1000-4000pg/ml，更佳地1200-2500pg/ml，更佳地1400-2000pg/ml，更佳地1600-2000pg/ml，更佳地1700-1900pg/ml；
    在所述的无细胞脂肪提取物中，所述的bFGF的浓度为50-600pg/ml，较佳地100-500pg/ml，更佳地120-400pg/ml，更佳地150-300pg/ml，更佳地200-280pg/ml，更佳地220-260pg/ml；
    在所述的无细胞脂肪提取物中，所述的VEGF的浓度为50-500pg/ml，较佳地100-400pg/ml，更佳地120-300pg/ml，更佳地150-250pg/ml，更佳地170-230pg/ml，更佳地190-210pg/ml；
    在所述的无细胞脂肪提取物中，所述的TGF-β1的浓度为200-3000pg/ml，较佳地400-2000pg/ml，更佳地600-1500pg/ml，更佳地800-1200pg/ml，更佳地800-1100pg/ml，更佳地900-1000pg/ml；
    在所述的无细胞脂肪提取物中，所述的HGF的浓度为200-3000pg/ml，较佳地400-2000pg/ml，更佳地600-1500pg/ml，更佳地600-1200pg/ml，更佳地800-1000pg/ml，更佳地850-950pg/ml；和/或
    在所述的无细胞脂肪提取物中，所述的PDGF的浓度为50-600pg/ml，较佳地80-400pg/ml，更佳地100-300pg/ml，更佳地140-220pg/ml，更佳地160-200pg/ml，更佳地170-190pg/ml。
  8. 如权利要求6所述的用途，其特征在于，所示的无细胞脂肪提取物包括选自下组的一种或多种特征：
    所述的IGF-1与VEGF的重量比为20-100：1，较佳地30-70：1，更佳地40-60：1，最佳地45-55：1；
    所述的BDNF与VEGF的重量比为2-20：1，较佳地4-15：1，更佳地6-12：1，最佳地8-9.5：1；
    所述的GDNF与VEGF的重量比为2-20：1，较佳地4-15：1，更佳地6-12：1，最佳地8.5-9.5：1；
    所述的bFGF与VEGF的重量比为0.2-8：1，较佳地0.5-5：1，更佳地0.6-2：1，更佳地0.8-1.6：1，最佳地1-1.5：1；
    所述的TGF-β1与VEGF的重量比为1-20：1，较佳地1-15：1，更佳地1-10：1，更佳地2-8：1，更佳地4-6：1；
    所述的HGF与VEGF的重量比为1-20：1，较佳地1-15：1，更佳地1-10：1，更佳地2-8：1，更佳地4-5.5：1；和/或
    所述的PDGF与VEGF的重量比为0.1-3：1，较佳地0.2-2：1，更佳地0.4-1.5：1，最佳地0.7-1.2：1。
  9. 如权利要求1所述的用途，其特征在于，所述的无细胞脂肪提取物通过以下方法制备：
    (1)提供一脂肪组织原料，将所述脂肪组织原料破碎，并进行漂洗(如用生理盐水)，从而获得经漂洗的脂肪组织；
    (2)对所述经漂洗后的脂肪组织进行离心，获得分层的混合物；
    (3)对所述分层的混合物，去除上层油层和下层水层，收集中间层(即含脂肪细胞的脂肪层)；
    (4)对所述中间层进行乳化，获得乳化的脂肪混合物(也称为纳米脂肪)；
    (5)将所述乳化的脂肪混合物通过离心处理，从而获得中间液体层，即为脂肪初提物；和
    (6)对所述脂肪初提物进行过滤和除菌，从而获得无细胞的脂肪提取物。
  10. 一种(i)预防和/或治疗勃起功能障碍；和/或(ii)预防和/或治疗阴茎海绵体神经损伤的方法，其特征在于，对需要的对象施用无细胞脂肪提取物。
PCT/CN2021/140982 2020-12-24 2021-12-23 〈无细胞脂肪提取物对勃起功能障碍的治疗用途〉 WO2022135545A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202011547887.8 2020-12-24
CN202011547887.8A CN114668779A (zh) 2020-12-24 2020-12-24 无细胞脂肪提取物对勃起功能障碍的治疗用途

Publications (1)

Publication Number Publication Date
WO2022135545A1 true WO2022135545A1 (zh) 2022-06-30

Family

ID=82070064

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2021/140982 WO2022135545A1 (zh) 2020-12-24 2021-12-23 〈无细胞脂肪提取物对勃起功能障碍的治疗用途〉

Country Status (2)

Country Link
CN (1) CN114668779A (zh)
WO (1) WO2022135545A1 (zh)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011051908A (ja) * 2009-08-31 2011-03-17 Univ Of Tokyo 勃起障害治療用組成物
CN105902568A (zh) * 2016-04-29 2016-08-31 张宁 用于治疗勃起功能障碍的脂肪间充质干细胞
CN107412264A (zh) * 2017-05-10 2017-12-01 健生生物技术有限公司 用于治疗男性勃起障碍的药物及其制备和使用方法
CN108392493A (zh) * 2018-04-10 2018-08-14 上海交通大学医学院附属仁济医院 一种用于治疗勃起功能障碍的含细胞外囊泡的可注射水凝胶及其制备方法
CN108498452A (zh) * 2018-04-10 2018-09-07 上海交通大学医学院附属仁济医院 一种用于治疗勃起功能障碍的含干细胞可注射水凝胶及其制备方法
CN110496241A (zh) * 2018-05-16 2019-11-26 上海交通大学医学院附属第九人民医院 取自脂肪组织的生物材料及其制备方法和用途
CN111419877A (zh) * 2020-03-13 2020-07-17 北京中瑞联合生物科技有限公司 一种用于治疗男性勃起障碍的药物及其制备方法

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011051908A (ja) * 2009-08-31 2011-03-17 Univ Of Tokyo 勃起障害治療用組成物
CN105902568A (zh) * 2016-04-29 2016-08-31 张宁 用于治疗勃起功能障碍的脂肪间充质干细胞
CN107412264A (zh) * 2017-05-10 2017-12-01 健生生物技术有限公司 用于治疗男性勃起障碍的药物及其制备和使用方法
CN108392493A (zh) * 2018-04-10 2018-08-14 上海交通大学医学院附属仁济医院 一种用于治疗勃起功能障碍的含细胞外囊泡的可注射水凝胶及其制备方法
CN108498452A (zh) * 2018-04-10 2018-09-07 上海交通大学医学院附属仁济医院 一种用于治疗勃起功能障碍的含干细胞可注射水凝胶及其制备方法
CN110496241A (zh) * 2018-05-16 2019-11-26 上海交通大学医学院附属第九人民医院 取自脂肪组织的生物材料及其制备方法和用途
CN111419877A (zh) * 2020-03-13 2020-07-17 北京中瑞联合生物科技有限公司 一种用于治疗男性勃起障碍的药物及其制备方法

Also Published As

Publication number Publication date
CN114668779A (zh) 2022-06-28

Similar Documents

Publication Publication Date Title
WO2021143912A1 (zh) 无细胞脂肪提取液对脂肪肝及其并发症的治疗作用
KR20150083467A (ko) 과민성 방광 및 방광의 염증 치료 또는 예방용 조성물
TW201713330A (zh) 肌肉脂肪化抑制用組成物
WO2021249561A1 (zh) 无细胞脂肪提取液对肺部疾病的治疗用途
WO2022170940A1 (zh) 无细胞脂肪提取物用于改善衰老和促进皮肤年轻化
WO2022135545A1 (zh) 〈无细胞脂肪提取物对勃起功能障碍的治疗用途〉
CN112755035A (zh) 牛磺熊脱氧胆酸在治疗新生儿坏死性小肠结肠炎中的应用
WO2022028375A1 (zh) 无细胞脂肪提取液对肺部疾病的治疗用途
US20040109899A1 (en) Antiviral medicament and method for producing and using the same for the prophylactic and therapeutic treatment of papillomavirus induced tumors, lesions and deseases
WO2020062780A1 (zh) 防治缺血性心脏病或缺血性脑病或血栓形成的药物及应用
WO2021249402A1 (zh) 无细胞脂肪提取液对巨噬细胞极化调节与疾病治疗的作用
WO2022194094A1 (zh) 无细胞脂肪提取物用于治疗脊髓损伤
WO2023020178A1 (zh) 无细胞脂肪提取物用于治疗阴道萎缩
WO2022100400A1 (zh) 无细胞脂肪提取液对非酒精性脂肪肝炎的治疗用途
WO2023284466A1 (zh) 无细胞脂肪提取物用于治疗卵巢功能不全
WO2022116983A1 (zh) 无细胞脂肪提取液对骨质疏松症的治疗用途
WO2022100399A1 (zh) 无细胞脂肪提取液对关节炎的治疗用途
WO2022170939A1 (zh) 无细胞脂肪提取物对视神经损伤的治疗用途
WO2022095715A1 (zh) 无细胞脂肪提取液对溃疡性结肠炎的治疗用途
WO2022194093A1 (zh) 无细胞脂肪提取物用于治疗非增生性瘢痕
CN107308145B (zh) 苯乙双胍在制备抗皮肤炎症制剂中的用途
El-Mofty et al. Studies on the Mode of Action of Psoralen Derivatives: I. Their Effect on Copper and Glutathione Levels in Blood and Liver
JP4599480B2 (ja) 感染免疫機能強化剤、新陳代謝機能促進剤、生体諸機能低下予防改善剤及びこれらを含有する機能食品
JP2014015428A (ja) サテライト細胞分化促進剤
CN117398413A (zh) 无细胞脂肪提取物用于治疗卵巢功能不全

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21909540

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21909540

Country of ref document: EP

Kind code of ref document: A1